Journey to the Diagnosis of Generalized Pustular Psoriasis (GPP)

This is a video synopsis/summary of a panel discussion involving Tina Bhutani, MD; J. Scott Boswell, MD; and Kanya Oul, RN.

The discussion revolves around Generalized Pustular Psoriasis (GPP), a chronic and potentially life-threatening condition. Despite its severity, there remains a lack of understanding among healthcare providers regarding its diagnosis and treatment initiation, leading to significant delays in patient care.

The conversation includes insights from a dermatologist and a patient undergoing treatment for GPP.

The patient shares her journey with GPP, which began with symptoms manifesting as a diaper rash at 2 years old. Diagnosis took approximately a year, during which she experienced various treatments including psoriatane, cyclosporine, and prednisone, leading to fluctuations in her condition. Her health stabilized upon starting etanercept, but stress during her nursing program triggered severe flare-ups, eventually leading her to the care of her current dermatologist.

The dermatologist elaborates on GPP's characteristics, noting a predominance in female and Asian patients, and genetic factors such as interleukin-36 receptor deficiencies, which can exacerbate symptoms. GPP patients are at risk of hospitalization due to complications like sepsis and electrolyte imbalances. Severe cases can progress to erythrodermic psoriasis, increasing the risk of organ failure.

The transcript underscores the importance of early detection and management of GPP to prevent life-threatening complications. Through patient testimonies and medical insights, the discussion aims to raise awareness among healthcare providers and improve outcomes for individuals living with GPP.

Video synopsis is AI-generated and reviewed by HCPLive editorial staff.